ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 950,17
0,11%
Dow Jones
44 544,66
-0,75%
DAX
21 732,05
0,01%
Brent Oil
76,385
0,00%
Bitcoin
102 476,28
0,06%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) Actualités

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RNAZ
DateHeureSourceTitreSymboleSociété
14/01/202514h00PR Newswire (US)TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
07/01/202514h00PR Newswire (US)Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
30/12/202423h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
20/12/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
19/12/202422h48Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
18/12/202414h00PR Newswire (US)TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
18/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
12/12/202422h15Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RNAZTransCode Therapeutics Inc
06/12/202423h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
29/11/202422h25GlobeNewswire Inc.TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
27/11/202413h00GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces $8 Million Private PlacementNASDAQ:RNAZTransCode Therapeutics Inc
25/11/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces 1-for-33 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
13/11/202422h34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
12/11/202413h00GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
06/11/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
05/11/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceNASDAQ:RNAZTransCode Therapeutics Inc
23/10/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety DataNASDAQ:RNAZTransCode Therapeutics Inc
10/10/202413h00GlobeNewswire Inc.TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted TechnologyNASDAQ:RNAZTransCode Therapeutics Inc
17/09/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateNASDAQ:RNAZTransCode Therapeutics Inc
10/09/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic CancerNASDAQ:RNAZTransCode Therapeutics Inc
05/09/202413h00GlobeNewswire Inc.TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateNASDAQ:RNAZTransCode Therapeutics Inc
15/08/202413h00GlobeNewswire Inc.TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationNASDAQ:RNAZTransCode Therapeutics Inc
14/08/202422h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAZTransCode Therapeutics Inc
26/07/202422h05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202422h05GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Closing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202414h18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAZTransCode Therapeutics Inc
23/07/202404h30GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Pricing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
22/07/202422h07GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAZTransCode Therapeutics Inc
18/06/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202414h00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAZ

Dernières Valeurs Consultées

USOTC
ARRT
Artisan Consumer Goods (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces